DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic

Molecular Cancer Therapeutics

Volumn 3, Issue 5, 2004, Pages 577-585

  Tu, Lan Chun ^a   Melendy, Thomas ^b   Beerman, Terry A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25A; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN E; DNA; HEDAMYCIN; PHOSPHOTRANSFERASE; PLURAMYCIN; PROTEIN P21; PROTEIN P53; RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ALKYLATION; DNA DAMAGE; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EXPOSURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS;

ALKYLATING AGENTS; AMINOGLYCOSIDES; ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; CDC25 PHOSPHATASE; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN E; CYTOTOXINS; DNA; DNA DAMAGE; DNA NUCLEOTIDYLEXOTRANSFERASE; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BIOSYNTHESIS; RNA; S PHASE; TRANSCRIPTION FACTORS;

EID: 4444270619     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72.
2. Weinert T. DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 1998;94:555-8.
3. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
4. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39.
5. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71-7.
6. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
7. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9.
8. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
9. Decraene D, Agostinis P, Bouillon R, Degreef H, Garmyn M. Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human keratinocytes. J Biol Chem 2002;277:32587-95.
10. Chang D, Chen F, Zhang F, McKay BC, Ljungman M. Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest. Cell Growth & Differ 1999;10:155-62.
11. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999;18: 583-92.
12. Abbas T, Olivier M, Lopez J, et al. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 2002;277:40513-9.
13. Kang SG, Chung H, Yoo YD, Lee JG, Choi YI, Yu YS. Mechanism of growth inhibitory effect of mitomycin-C on cultured human retinal pigment epithelial cells: apoptosis and cell cycle arrest. Curr Eye Res 2001; 22:174-81.
14. Cao PR, McHugh MM, Melendy T, Beerman T. The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells. Mol Cancer Ther 2003;2:651-9.
15. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002;277:41580-9.
16. Bradner WT, Heinemann B, Gourevitch A. Hedamycin, a new antitumor antibiotic. II. Biological properties. Antimicrob Agents Chemother 1966;6:613-8.
17. Schmitz H, Crook KE Jr, Bush JA. Hedamycin, a new antitumor antibiotic. I. Production, isolation, and characterization. Antimicrob Agents Chemother 1966;6:606-12.
18. Murray V, Moore AG, Matias C, Wickham G. The interaction of hedamycin and DC92-B in a sequence selective manner with DNA in intact human cells. Biochim Biophys Acta Gene Struct Expr 1995;1261: 195-200.
19. Hansen M, Yun S, Hurley L. Hedamycin intercalates the DNA helix and, through carbohydrate-mediated recognition in the minor groove, directs N7-alkylation of guanine in the major groove in a sequence-specific manner. Chem Biol 1995;2:229-40.
20. Cairns MJ, Murray V. The DNA sequence specificity of hedamycin damage determined by ligation-mediated PCR and linear amplification. Biochem Mol Biol Int 1998;46:267-75.
21. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997;208:151-8.
22. McHugh MM, Woynarowski JM, Gawron LS, Otani T, Beerman, TA. Effects of the DNA-damaging enediyne C-1027 on intracellular SV40 and genomic DNA in green monkey kidney BSC-1 cells. Biochemistry 1995;34:1805-14.
23. Bhuyan BK, Smith KS, Adams EG, Wallace TL, Von Hoff DD, Li LH. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother Pharmacol 1992;30:348-54.
24. 1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-90.
25. 2 arrest after DNA damage. Science 1998;282:1497-501.
26. Boddy MN, Furnari B, Mondesert O, Russell P. Replication checkpoint enforced by kinases Cds1 and Chk1. Science 1998;280:909-12.
27. Galaktionov K, Lee AK, Eckstein J, et al. CDC25 phosphatases as potential human oncogenes. Science 1995;269:1575-7.
28. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9.
29. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-5.
30. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62.
31. 1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
32. Donaldson AD, Blow JJ. DNA replication: stable driving prevents fatal smashes. Curr Biol 2001;11:R979-82.
33. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-6.
34. Martinez LA, Yang J, Vazquez ES, et al. M. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002;23:1289-96.
35. Han Z, Wei W, Dunaway S, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 2002;277:17154-60.
36. Gervais JL, Seth P, Zhang H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 1998;273:19207-12.
37. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997;14:929-35.
38. Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;1:553-63.
39. Pan ZQ, Reardon JT, Li L, et al. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 1995;270: 22008-16.
40. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
41. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-7.
42. Stivala LA, Riva F, Cazzalini O, Savio M, Prosperi E. p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair down-stream the recruitment of PCNA to DNA repair sites. Oncogene 2001; 20:563-70.
43. Feijoo C, Hall-Jackson C, Wu R, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk 1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154:913-23.
44. Furstenthal L, Kaiser BK, Swanson C, Jackson PK. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 2001;152:1267-78.
45. Kilbey A, Stephens V, Bartholomew C. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth & Differ 1999;10:601-10.
46. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001;15:1833-44.
47. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
48. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002;529:122.
49. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 1999; 19:3704-13.
50. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994;91:3602-6.
51. Hsieh JK, Yap D, O'Connor DJ, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 2002;22:78-93.
52. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002;302:8-17.
53. Zhang ZW, Patchett SE, Farthing MJ. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 2000;11:757-64.
54. 2 cells by 10-hydroxycamptothecin. Anticancer Drugs 1999;10:569-76.
55. Fornari FA Jr, Jarvis DW, Grant S, et al. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 1996;51:931-40.
56. Ababou M, Dutertre S, Lécluse Y, Onclercq R, Chatton B, Amor-Guéret M. ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation. Oncogene 2000;19: 5955-63.
57. 1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001;13:738-47.
58. Cobuzzi RJ Jr, Burhans WC, Beerman TA. Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin. J Biol Chem 1996;271:19852-9.